期刊文献+

Survivin在T细胞非霍奇金淋巴瘤组织中的表达及临床意义 被引量:7

Clinical Significance of Survivin Expression in T-cell Non-Hodgkin's Lymphoma
暂未订购
导出
摘要 【目的】了解生存蛋白Survivin在T细胞非霍奇金淋巴瘤(T-NHL)中的表达,以及Survivin表达与预后的关系。【方法】用免疫组化S-P法检测83例T细胞NHL组织Survivin表达情况,分析Survivin表达与预后的关系。【结果】Survivin表达阴性10例(12%),表达阳性73例(88%),Survivin表达与病理类型、性别、年龄、B症状、结外病变数、PS、分期、LDH水平、IPI等临床特征均无相关性(P>0.05)。78例接受了化疗,大多数采用CHOP方案化疗,全组CR率45%,有效率86%,Survivin阴性者CR率60%,阳性者43%(P>0.05)。中位随访22月(1~76月),全组5年生存率31%,Survivin表达阳性的T-NHL患者5年生存率明显低于Survivin表达阴性患者(21%比70%,P<0.001)。多因素分析显示Survivin表达是T细胞NHL的独立预后指标。【结论】Survivin在T细胞NHL表达上调,Survivin阳性T-NHL患者5年生存率低于Survivin阴性者,Survivin表达可能为T细胞NHL预后的独立指标。 [Objectives ] This study was designed to evaluate the expression of survivin in T-cell non-Hodgkin's lymphoma (T-NHL) and the correlation of survivin expression and prognosis. [Methods] Expression of survivin in T- NHL tissues were detected by immunohistochemical staining (S-P method). The relationship between survivin expression and prognosis were analyzed among 83 patients. [Results] Ten patients showed negative survivin expression (12%), Seventy-three showed positive survivin expression (88%). Survivin expression was not related to the pathological subtypes, stage, LDH, extranodal sites, B symptoms and IPI score in our study (P 〉0.05). Most of the patients were treated by combined chemotherapy (CHOP regimen). The overall response rate was 86% with 45% complete remission (CR) rates. The patients with positive survivin expression tend to be lower in CR rate (43% vs 60%, P 〉0.05). The 5-year overall survival for the patients with negative survivin expression was longer than that of the patients with positive survivin expression (21% vs 70%, P〈 0.001). The results of multivariant analysis showed survivin was an independent prognostic factor for T-NHL. [Conclusion] Up-regulation of survivin expression in T- NHL is observed in our study. The 5-year overall survival of the patients with positive survivin was shorter than that of the patients with negative survivin expression. Expression of survivin may be an independent prognostic factor for T-NHL based on our study.
出处 《中山大学学报(医学科学版)》 CAS CSCD 北大核心 2006年第2期221-224,231,共5页 Journal of Sun Yat-Sen University:Medical Sciences
关键词 淋巴瘤 T细胞 病理学 SURVIVIN 预后 lymphomas, T-cell/pathology survivin prognosis
  • 相关文献

参考文献12

  • 1KAWASAKI H,ALTIERI D C,LU C D,et al.Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer[J].Cancer Res,1998,58(22):5071-5074.
  • 2黄慧强,彭玉龙,林旭滨,孙晓菲,林桐榆,夏忠军,李宇红,蔡清清,何友兼,姜文奇,管忠震.CHOP方案治疗106例外周T细胞淋巴瘤的临床长期随访结果分析[J].癌症,2004,23(z1):1443-1447. 被引量:25
  • 3ADIDA C,HAIOUN C,GAULARD P,et al.Prognostic significance of survivin expression in diffuse large Bcell lymphomas[J].Blood,2000,96(5):1921-1925.
  • 4SCHLErTTE E J,MEDEIROS L J,GOY A,et al.Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma[J].J Clin Oncol,2004,22(9):1682-1688.
  • 5SHIN S,SUNG B J,CHOY S,et al.An anti-apoptotic protein human survivin is a direct inhibitor of caspase3and 7[J].Biochemistry,2001,40(4):1117-1123.
  • 6SPAN P N,SWEEP F C,WIEGERINCK E T.et al.Survivin is an independent prognostic marker for risk stratification of breast cancer patients[J].Clin Chem,2004,50(11):1986-1993.
  • 7SHINOHARA E T,GONZALEZ A,MASSION P P,et al.Nuclear survivin predicts recurrence and poor survival in patients with resected non small cell lung carcinoma[J].Cancer,2005,103(8):1685-1692.
  • 8ITO R,ASAMI S,MOTOHASHI S,et al.Significance of survivin mRNA expression in prognosis of neuroblastoma[J].Biol pharm Bull,2005,28(4):565-568.
  • 9罗俊航,陈炜,戴宇平,陈凌武,石华,廖冰.CD44v6和survivin在膀胱移行细胞癌中的表达及其意义[J].中山大学学报(医学科学版),2004,25(B06):79-80. 被引量:2
  • 10向晓娟,何友兼.弥漫大B细胞淋巴瘤survivin表达与临床预后关系探讨[J].中国肿瘤临床,2004,31(9):509-512. 被引量:13

二级参考文献47

  • 1[1]Kim K, Kim WS, Jung CW, et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the REAL classification [J]. Eur J Cancer, 2002, 38 (1): 75 - 81.
  • 2[2]Edward R, Arrowsmit H, William R, et al. Peripheral T-cell Lymphomas: clinical features and prognostic factors of 92 cases defined by the Revised European American lymphoma classification [J]. Leuk Lymphoma, 2003, 44(2) :241 - 249.
  • 3[3]Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified(PTCL-U): a new prognostic model from a retrospective multicentric clinical study [J] . Blood, 2004, 103(7): 2474 - 2479.
  • 4[4]Rudiger T, Weisenburger DD, Anderson JR, et al. Peripheral T-cell lymphoma(excluding anaplastic large-cell lymphoma):results from the Non-Hodgkin's Lymphoma classification project [J].Ann Oncol, 2002, 13 ( 1 ): 140 - 149.
  • 5[5]Lee HK, Wilder RB, Jones D, et al. Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas [J]. Leu Lymphoma,2002, 43(9): 1769 - 1775.
  • 6[6]Pellatt J, Sweetenham J, Pickering RM, et al. A single-centre study of treatment outcomes and survival in 120 patients with peripheral T-cell non-Hodgkin's lymphoma [J]. Ann Hematol, 2002, 81 (5):267 - 272.
  • 7[7]Lopez-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphoma: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL Classification [J]. Ann Oncol, 1998, 9(8): 849 - 855.
  • 8[8]Harris NL, Jaffe ES, Stein H, et al. A revised European-American classfication of Lmphoid neoplasms: a proposal from the international lymphoma study group [J]. Blood, 1994, 84(5):1361 - 1392.
  • 9[9]Zaja F, Russo D, Silvestri F, et al. Retrospective analysis of 23cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome [J]. Hematologica, 1997, 82(2):171 - 177.
  • 10[10]Liang R, Todd D, Chan TK, Chiu E, et al. Intensive chemotherapy for peripheral T-cell lymphomas. Hematol Oncol, 1992, 10(3 -4): 155 - 161.

共引文献54

同被引文献82

引证文献7

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部